Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Yale University · Central Dermatology · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
274
total citations
- FWCI
- 20.87
- Percentile
- 100%
- References
- 19
Citations per year
Authors
16Topics & keywords
Topics
Keywords
- Apremilast
- Medicine
- Psoriasis
- Placebo
- Adverse effect
- Psoriasis Area and Severity Index
- Internal medicine
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.